Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
Received 1 November 2019
Accepted for publication 20 January 2020
Published 24 February 2020 Volume 2020:11 Pages 17—24
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Young Lyoo
István Kiss,1 Edit Kovács,1 Zoltán Zádori,2 István Mészáros,2 Attila Cságola,1 Pál Bajnóczi,3 Preben Mortensen,4 Vilmos Palya1
1Ceva-Phylaxia Co. Ltd., Budapest, Hungary; 2Institute for Veterinary Medical Research, Centre for Agricultural Research, Budapest, Hungary; 3Prophyl Ltd., Mohács, Hungary; 4Ceva Animal Health, Libourne, France
Correspondence: István Kiss
Ceva-Phylaxia Co. Ltd., Szállás U. 5, Budapest H-1107, Hungary
Tel +36 1262 9505
Fax +36010260 3889
Background/Introduction: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines.
Methods: To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared.
Results: The K22 vaccine strain of Parvoruvax® (PVX) was characterized as “Kresse-like” based on the epitope mapping data. Vaccination of the gilts induced a low level of antibody responses. Based on foetal mortality, the number of sows which had challenge virus-affected foetuses, the percent of PPV positive piglets/litters plus their PPV genome and viral load PVX outscored the other vaccinated groups.
Conclusion: Stronger protection was provided by the “Kresse-like” K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection.
Keywords: PPV, K22 strain, efficacy, PPV-27a
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]